These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 25084527

  • 21. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J, MermaiHD study investigators.
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [Abstract] [Full Text] [Related]

  • 22. Therapeutic advances in Huntington's Disease.
    Shannon KM, Fraint A.
    Mov Disord; 2015 Sep 15; 30(11):1539-46. PubMed ID: 26226924
    [Abstract] [Full Text] [Related]

  • 23. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
    Gibrat C, Cicchetti F.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar 30; 35(2):380-9. PubMed ID: 21111020
    [Abstract] [Full Text] [Related]

  • 24. An experimental model for Huntington's chorea?
    Zeef DH, Jahanshahi A, Vlamings R, Casaca-Carreira J, Santegoeds RG, Janssen ML, Oosterloo M, Temel Y.
    Behav Brain Res; 2014 Apr 01; 262():31-4. PubMed ID: 24412685
    [Abstract] [Full Text] [Related]

  • 25. Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms.
    Johnston TG.
    Int Clin Psychopharmacol; 2011 Mar 01; 26(2):114-9. PubMed ID: 21119522
    [Abstract] [Full Text] [Related]

  • 26. Zotepine in Huntington's disease.
    Bonelli RM, Niederwieser G, Lahousen T, Hofmann P.
    Hum Psychopharmacol; 2003 Apr 01; 18(3):227-9. PubMed ID: 12672176
    [Abstract] [Full Text] [Related]

  • 27. Using Drosophila models of neurodegenerative diseases for drug discovery.
    Newman T, Sinadinos C, Johnston A, Sealey M, Mudher A.
    Expert Opin Drug Discov; 2011 Feb 01; 6(2):129-40. PubMed ID: 22647132
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB, Dubois B, de Yébenes JG, Kremer B, Gaus W, Kraus PH, Przuntek H, Dib M, Doble A, Fischer W, Ludolph AC, European Huntington's Disease Initiative Study Group.
    Ann Neurol; 2007 Sep 01; 62(3):262-72. PubMed ID: 17702031
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Huntington's disease presenting as amyotrophic lateral sclerosis.
    Phukan J, Ali E, Pender NP, Molloy F, Hennessy M, Walsh RJ, Hardiman O.
    Amyotroph Lateral Scler; 2010 Aug 01; 11(4):405-7. PubMed ID: 19530012
    [Abstract] [Full Text] [Related]

  • 34. Discontinued drugs 2011: endocrine and metabolic.
    Colca JR.
    Expert Opin Investig Drugs; 2012 Nov 01; 21(11):1619-24. PubMed ID: 22917013
    [Abstract] [Full Text] [Related]

  • 35. [A new treatment of Huntington's chorea. Report of three cases (author's transl)].
    Zenglein JP, Baldauf E, Hussaini M.
    Sem Hop; 2012 Nov 01; 54(25-28):871-4. PubMed ID: 214869
    [Abstract] [Full Text] [Related]

  • 36. New renal drug development to face chronic renal disease.
    Moll S, Meier M, Formentini I, Pomposiello S, Prunotto M.
    Expert Opin Drug Discov; 2014 Dec 01; 9(12):1471-85. PubMed ID: 25195802
    [Abstract] [Full Text] [Related]

  • 37. Preclinical assessment programs to evaluate potential therapies for the treatment of orphan retinal diseases.
    Schoen T.
    Retina; 2005 Dec 01; 25(8 Suppl):S64-S65. PubMed ID: 16374343
    [No Abstract] [Full Text] [Related]

  • 38. Participant-funded clinical trials on rare diseases.
    Dal-Ré R, Palau F, Guillén-Navarro E, Ayuso C.
    An Pediatr (Engl Ed); 2020 Oct 01; 93(4):267.e1-267.e9. PubMed ID: 34092344
    [Abstract] [Full Text] [Related]

  • 39. Publisher Correction: Questions swirl around failures of disease-modifying Huntington's drugs.
    Sheridan C.
    Nat Biotechnol; 2021 Jul 01; 39(7):893. PubMed ID: 34155408
    [No Abstract] [Full Text] [Related]

  • 40. Publisher Correction: Questions swirl around failures of disease-modifying Huntington's drugs.
    Sheridan C.
    Nat Biotechnol; 2021 Aug 01; 39(8):1017. PubMed ID: 34312502
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.